PAR-25-346-Full-Announcement.html

This is an HTML announcement file for PAR-25-346, an Exploratory/Developmental Bioengineering Research Grants (EBRG) opportunity offered by the National Cancer Institute (NCI) under the Department of Health and Human Services. The R21 grant mechanism supports exploratory/developmental research projects focused on demonstrating feasibility and utility of new bioengineering capabilities in basic biomedical, pre-clinical, clinical research, and healthcare delivery.

The opportunity is open to a wide range of applicants including higher education institutions, tribal organizations, nonprofits, for-profit organizations, and government entities. It falls under multiple CFDA programs including Cancer Detection and Diagnosis Research (93.394), Cancer Treatment Research (93.395), Cancer Cause and Prevention Research (93.393), Oral Diseases Research (93.121), Cancer Control (93.399), and Cancer Biology Research (93.396). The grant specifically excludes clinical trials. The focus is on engineering-oriented solutions that improve quality, speed, efficacy, operability, costs, and accessibility of biomedical research and clinical care delivery.